Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo. Plaque psoriasis, a chronic ...

evaluated the safety and efficacy of icotrokinra in 311 adults and adolescents 12 years of age and older with plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and ...